Drug LT3001 for sudden stroke symptoms within 24 hours
Part of Brain & nervous system, Heart & circulation clinical trials.
This Phase 2 study tests LT3001 to improve recovery after an acute ischemic stroke (a stroke caused by blocked blood flow). It is designed for people who can be treated within 24 hours of symptom onset and who meet specific safety and health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old at screening
- You were diagnosed with an acute ischemic stroke, and your symptoms are measurable
- You can start the study drug within 24 hours of when your stroke symptoms began
- Your blood pressure and blood sugar meet safe limits after treatment (no very high BP, not very low/high sugar)
- You are able to consent (sign the consent form) yourself or with a guardian
- You are able to cooperate with study checks (not unusually confused or unable to follow instructions)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational injectable drug called LT3001 that may help dissolve blood clots in the brain after a stroke. It is given within 24 hours of stroke onset, and the goal is to reduce disability and improve recovery.
This trial tests whether MT200605 can help people who recently had an ischemic stroke (a type of stroke caused by a blocked blood vessel). The drug is given within 24 hours of symptoms starting, and you may join even if you received clot-busting treatment already.
This trial tests an investigational injection called KPCXM18 for people having an acute ischemic stroke. It is given within 12 hours of symptom onset, in addition to standard clot-dissolving treatment, to see if it improves recovery and safety.
This trial tests a new drug called BB-031 for people who have had a stroke caused by a blocked blood vessel in the brain. The drug may help restore blood flow and reduce damage if given within 24 hours of symptoms starting.
This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.
This trial tests a clot-busting drug for people who had a stroke but don't know when it started, like waking up with symptoms. It may help reduce disability if given soon after noticing symptoms.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.